The proposed book entitled, “Anti HIV Drugs: Non-Nucleoside Reverse Transcriptase Inhibitors” gives an outline of the Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) class of Anti HIV drugs, from the initial discovery of the class in 1990 to the current compounds in clinical development, i.e. around 20 years of research and development efforts. It describes the characteristics of the NNRTIs, their mechanisms of action, HIV resistance to the inhibitors, and the drugs that have been approved for the treatment of HIV infection, that are currently in clinical development. The role of NNRTIs in prevention of HIV transmission is also addressed. The book also covers some basic information about HIV, AIDS and HIV life cycle.
Table of Contents
Chapter– 1: History
Chapter‒ 2: HIV Virus
2.1 Structure of HIV
2.2 HIV Life Cycle
2.2.1 Entry or Binding and Fusion
2.2.2 Reverse Transcription (RT)
2.2.3 Integration (IN)
2.2.4 Transcription
2.2.5 Assembly
2.2.6 Budding
2.2.7 Maturation
Chapter‒ 3: Anti HIV Drugs
3.1 Classification of Anti HIV Drugs
3.1.1 Entry Inhibitors
3.1.2 Integrase Inhibitors
3.1.3 Nucleoside (NRTI) and Nucleotide (NtRTIs) Reverse Transcriptase Inhibitors
3.1.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
3.1.5 Protease Inhibitors (PIs)
3.2 FDA approved Anti HIV Drugs
Chapter‒ 4: Non-Nucleoside Reverse Transcriptase Inhibitors
4.1 HIV Reverse Transcriptase (RT) enzyme
4.2 Mechanism of action of NNRTIs
Chapter‒ 5: Important classes of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.1 TIBO {4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepine-2(1H)-ones} derivatives
5.2 HEPT {1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine}
5.3 Pyridinones
5.4 Thiocarboxanilide derivatives
5.5 DABO {Dihydroalkoxybenzyloxopyrimidine}
5.6 DATA {Diaryl triazine}
5.7 DAPYs {Diarylpyrimidines}
5.8 PBOs {Pyrrolobenzoxazepinones}
5.9 Benzoxazinones
5.10 2- Amino pyrimidine
5.11 Benzophenone
5.12 α-Anilinophenylacetamides (α-APAs)
5.13 Dipyridodiazepinones
5.14 PETT {Phenyl Ethyl Thiourea Thiazole}
5.15 BHAP {Bis (heteroaryl)-Piperazine} derivatives
Chapter‒ 6: HIV and drug resistance
Chapter‒ 7: Highly Active Antiretroviral Therapy
Chapter‒ 8: Conclusion
Objectives & Core Topics
The primary goal of this work is to provide a comprehensive analysis of the Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) class of drugs used for HIV treatment. The book traces the development of this therapeutic class from its initial discovery in 1990, examining drug characteristics, binding mechanisms, resistance patterns, and clinical progress.
- Historical evolution of HIV/AIDS and NNRTI drug discovery.
- Detailed analysis of the HIV life cycle as a target for pharmacological intervention.
- Structural and mechanistic insights into Reverse Transcriptase inhibition.
- Comprehensive review of fifteen distinct NNRTI chemical classes.
- Evaluation of drug resistance mechanisms and the role of highly active antiretroviral therapy (HAART).
Excerpt from the Book
4.2. Mechanism of action of NNRTIs:
A number of different mechanisms for NNRTI inhibition of Reverse Transcriptase have been proposed. An early suggestion was that the binding of Nevirapine induces so-called ‘molecular arthritis’ whereby relative domain movements, thought to be necessary for the catalytic cycle of the enzyme, are inhibited. Crystal structures of Reverse Transcriptase with bound NNRTIs generally have the p66 thumb subdomain in an extended position. For unliganded Reverse Transcriptase the thumb subdomain can either be folded down into the DNA–RNA binding cleft or can adopt a more extended position. Examination of various crystal forms of Reverse Transcriptase with different NNRTIs bound showed significant variations in relative domain positioning. Thus, there is no clear evidence that NNRTI binding induces a single positioning of the p66 thumb subdomain.
Comparing the NNRTI bound and free forms of Reverse Transcriptase indicated a significant and consistent movement of strands β2- β3 containing the critical Asp110, Asp185 and Asp186 active site triad. Such a distortion of the key catalytic residues can explain the inhibition of Reverse Transcriptase by NNRTIs (Figure 4.2) Parallel rapid reaction kinetic experiments showed that the rate limiting step inhibited was the chemical bond formation, in line with the proposed structural mechanism.
Summary of Chapters
Chapter– 1: History: Provides an overview of the identification of HIV as the causative agent of AIDS and summarizes global epidemiological data.
Chapter‒ 2: HIV Virus: Details the fundamental biological differences between unicellular organisms and viruses, focusing on the specific structure and replication cycle of HIV.
Chapter‒ 3: Anti HIV Drugs: Categorizes various groups of antiretroviral drugs and presents tables of FDA-approved therapies, including fusion, integrase, and reverse transcriptase inhibitors.
Chapter‒ 4: Non-Nucleoside Reverse Transcriptase Inhibitors: Examines the specific enzyme-inhibitor interaction, explaining the structural biology of the Reverse Transcriptase enzyme and its NNRTI binding site.
Chapter‒ 5: Important classes of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Explores fifteen distinct chemical classes of NNRTIs, covering their structure-activity relationships and design evolution.
Chapter‒ 6: HIV and drug resistance: Analyzes the mechanisms of viral resistance to existing inhibitors and the impact of mutations like Y181C and K103N.
Chapter‒ 7: Highly Active Antiretroviral Therapy: Discusses the transition to combination therapies (HAART) and their effectiveness in suppressing viral load and improving patient prognosis.
Chapter‒ 8: Conclusion: Synthesizes the need for continued research into higher-affinity compounds to combat rapid viral mutation and persistent resistance issues.
Keywords
HIV, AIDS, Reverse Transcriptase, NNRTI, Drug Resistance, Antiretroviral Therapy, HAART, Enzyme Inhibition, Molecular Docking, TIBO, HEPT, Pyridinones, Structural Biology, Pharmacophore, Viral Replication.
Frequently Asked Questions
What is the primary focus of this book?
The book focuses on the pharmacological and structural aspects of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) used in the treatment of HIV.
What are the core research themes?
Central themes include the discovery timeline of NNRTIs, the mechanism of action on viral enzymes, drug design, and the challenge of managing drug-resistant HIV strains.
What is the primary objective of the research?
The objective is to outline the development of NNRTIs over 20 years, explaining how their molecular structure interacts with the Reverse Transcriptase enzyme to stop viral replication.
What scientific methodology is utilized?
The work employs a review of existing literature, structure-activity relationship (SAR) analysis, and examinations of crystallography data to explain how different chemical classes inhibit the HIV enzyme.
What does the main body cover?
The main body covers the HIV life cycle, a detailed classification of antiretroviral drugs, and a technical deep-dive into fifteen specific classes of NNRTIs, including their structural interaction with the binding pocket.
Which keywords best characterize the work?
Key terms include HIV, NNRTI, Reverse Transcriptase, Antiretroviral Therapy, Drug Resistance, and Structure-Activity Relationship.
How do NNRTIs differ from NRTIs?
NNRTIs are non-competitive, highly specific inhibitors that bind to a distinct hydrophobic pocket on the Reverse Transcriptase enzyme, whereas NRTIs often act as chain terminators for DNA synthesis.
Why is Trp229 considered a significant residue?
Trp229 is a highly conserved residue in the hydrophobic binding pocket of the enzyme; because it is less prone to mutation, it serves as a critical target for the design of more resilient inhibitors.
- Citar trabajo
- Amit Patel (Autor), 2014, Anti HIV Drugs. Non-Nucleoside Reverse Transcriptase Inhibitors, Múnich, GRIN Verlag, https://www.grin.com/document/283092
